Navigation Links
Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
Date:7/28/2011

ANAHEIM, Calif., July 28, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:  QCOR) announced today that executive management will present at the Canaccord Genuity Growth Conference to be held August 9-11, 2011 at the InterContinental Boston in Boston, MA.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Thursday, August 11, 2011 at 9:00 a.m. ET.

To listen to the audio web cast of the presentation during or after the event, please visit: www.questcor.com.  The replay will be available for ninety days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports Solid Fourth Quarter Results
2. Questcor to Discuss Results From FDA Panel Meeting
3. Trading Halted Today in Questcor Pharmaceuticals Common Stock
4. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
5. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Questcor to Present at UBS Global Life Sciences Conference
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
11. Questcor Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... New York, NY (PRWEB) , ... May 26, ... ... cell researcher, founder of Mehling Orthopedics and chief medical officer of Blue Horizon ... Musculoskeletal Disease and Regeneration. The conference was held during May 5-6, 2016 in ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... to oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) ... In this new partnership, OncLive’s editorial and marketing teams will publicize and promote ...
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & ... over 20 years of experience in leading technology and human resources operations for ... university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , ...
Breaking Medicine News(10 mins):